Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 14;36(1):70.
doi: 10.1007/s40520-024-02711-z.

Association of circulating hsa-miRNAs with sarcopenia: the SarcoPhAge study

Affiliations

Association of circulating hsa-miRNAs with sarcopenia: the SarcoPhAge study

Marjorie Millet et al. Aging Clin Exp Res. .

Abstract

Objective: To identify a microRNA signature associated to sarcopenia in community-dwelling older adults form the SarcoPhAge cohort.

Methods: In a screening phase by next generation sequencing (NGS), we compared the hsa-miRome expression of 18 subjects with sarcopenia (79.6 ± 6.8 years, 9 men) and 19 healthy subjects without sarcopenia (77.1 ± 6 years, 9 men) at baseline. Thereafter, we have selected eight candidate hsa-miRNAs according to the NGS results and after a critical assessment of previous literature. In a validation phase and by real-time qPCR, we then analyzed the expression levels of these 8 hsa-miRNAs at baseline selecting 92 healthy subjects (74.2 ± 10 years) and 92 subjects with sarcopenia (75.3 ± 6.8 years). For both steps, the groups were matched for age and sex.

Results: In the validation phase, serum has-miRNA-133a-3p and has-miRNA-200a-3p were significantly decreased in the group with sarcopenia vs controls [RQ: relative quantification; median (interquartile range)]: -0.16 (-1.26/+0.90) vs +0.34 (-0.73/+1.33) (p < 0.01) and -0.26 (-1.07/+0.68) vs +0.27 (-0.55/+1.10) (p < 0.01) respectively. Has-miRNA-744-5p was decreased and has-miRNA-151a-3p was increased in the group with sarcopenia vs controls, but this barely reached significance: +0.16 (-1.34/+0.79) vs +0.44 (-0.31/+1.00) (p = 0.050) and +0.35 (-0.22/+0.90) vs +0.03 (-0.68/+0.75) (p = 0.054).

Conclusion: In subjects with sarcopenia, serum hsa-miRNA-133a-3p and hsa-miRNA-200a-3p expression were downregulated, consistent with their potential targets inhibiting muscle cells proliferation and differentiation.

Keywords: Circulating hsa-miRNAs; Next generation sequencing; Sarcopenia; TaqMan qPCR.

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interests to declare that are relevant to the content of this article.

Figures

Fig. 1
Fig. 1
Flow diagram describing the methodology
Fig. 2
Fig. 2
The serum expression levels of the eight miRs analyzed in the validation phase in individual groups of subjects with or without sarcopenia after normalization with the three control miRs and standardized to cel-miRNA-39. Data are shown using a box-and-whisker plot where boxes show the 25th, 50th (median) and 75th percentiles, and the ends of the whiskers indicate the maximum and minimum

References

    1. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:601. doi: 10.1093/ageing/afz046. - DOI - PMC - PubMed
    1. Javanmardifard Z, Shahrbanian S, Mowla SJ. MicroRNAs associated with signaling pathways and exercise adaptation in sarcopenia. Life Sci. 2021;285:119926. doi: 10.1016/j.lfs.2021.119926. - DOI - PubMed
    1. Petermann-Rocha F, Balntzi V, Gray SR, Lara J, Ho FK, Pell JP, et al. Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2022;13:86–99. doi: 10.1002/jcsm.12783. - DOI - PMC - PubMed
    1. Yilmaz O, Bahat G. Muscle mass adjustment method affects association of sarcopenia and sarcopenic obesity with metabolic syndrome. Geriatr Gerontol Int. 2019;19:272. doi: 10.1111/ggi.13609. - DOI - PubMed
    1. Ethgen O, Beaudart C, Buckinx F, Bruyere O, Reginster JY. The future prevalence of sarcopenia in Europe: a claim for public health action. Calcif Tissue Int. 2017;100:229–234. doi: 10.1007/s00223-016-0220-9. - DOI - PMC - PubMed